Status: Recruiting
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy. The research results are expected to provide new insights and breakthroughs for the treatment of advanced prostate cancer.
Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Tianjin Medical University Second HospitalUpdated: Oct 29, 2024Locations: 1
Eligibility criteria
Participants must be able to understand the procedures and methods of this study... [+8]
Individuals with a known history of allergies to the components of this medicati... [+15]